Yash Lohariwal, N. Das, Shahzad Mirza, N. Gandham, Rajashri Patil, Sahjid Mukhida, Heer Shah, Sameena Khan
{"title":"在马哈拉施特拉邦西部三级保健中心引起尿路感染的大肠杆菌中磷霉素敏感性","authors":"Yash Lohariwal, N. Das, Shahzad Mirza, N. Gandham, Rajashri Patil, Sahjid Mukhida, Heer Shah, Sameena Khan","doi":"10.55010/imcjms.17.008","DOIUrl":null,"url":null,"abstract":"Background and objective: Urinary tract infection(UTI) is one of the most common bacterial infections encountered in clinical practice. UTIs caused by extended-spectrum beta-lactamase (ESBL) AmpC and metallo-beta-lactamase (MBL) producing Escherichia coli (E. coli) are difficult to treat. Fosfomycin is an old antibiotic that has excellent bactericidal activity against a wide range of bacteria. This study aimed to determine the fosfomycin susceptibility of E. coli causing UTI in a tertiary care hospital in Western Maharashtra, India.\n\nMaterial and methods: The study was conducted at a tertiary care center in Pune, a city of Western Maharashtra, India. Urine samples from UTI cases yielding significant (> 1x 105 cfu/ml) growth of E. coli were included in study. E. coli isolates were tested for susceptibility to fosfomycin and a panel of antimicrobial agents by Kirby Bauer disc diffusion method. All the isolates were tested for production of ESBL, AmpC and MBL.\n\nResult: A total of 88 E. coli were isolated of which, 47 (53.40%) and 41 (46.59%) were from male and female patients respectively. Of the total E. coli isolates, 58 (65.9%) were from in-patient cases. Multi-drug resistance was found in 69 (78.40%) isolates and remaining 19 (21.6%) were resistant to different antimicrobials tested. All (100%) the MDR and non-MDR isolates were sensitive to fosfomycin. Highest resistance was present against nalidixic acid (93.8%) while resistance was least against nitrofurantoin (15.91%), piperacillin/tazobactam (17.1%) and meropenem (18.18%). Of the total, 35 (50.72%) isolates were both AmpC and ESBL producers while 11 (15.94%) and 8 (11.59%) were only AmpC and ESBL producers respectively. MBL was positive in 15 (21.73%) of E. coli isolates. All those isolates tested sensitive to fosfomycin.\n\nConclusion: The study revealed that fosfomycin had excellent activity against MDR E. coli causing UTI in our area.\n\nIMC J Med Sci. 2023; 17(1): 008. DOI: https://doi.org/10.55010/imcjms.17.008\n\n*Correspondence: Dr. Sameena Khan, Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India. E-mail: sameenak27@gmail.com","PeriodicalId":55816,"journal":{"name":"IMC Journal of Medical Science","volume":"131 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fosfomycin susceptibility among Escherichia coli causing urinary tract infection in a tertiary care centre in Western Maharashtra\",\"authors\":\"Yash Lohariwal, N. Das, Shahzad Mirza, N. Gandham, Rajashri Patil, Sahjid Mukhida, Heer Shah, Sameena Khan\",\"doi\":\"10.55010/imcjms.17.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and objective: Urinary tract infection(UTI) is one of the most common bacterial infections encountered in clinical practice. UTIs caused by extended-spectrum beta-lactamase (ESBL) AmpC and metallo-beta-lactamase (MBL) producing Escherichia coli (E. coli) are difficult to treat. Fosfomycin is an old antibiotic that has excellent bactericidal activity against a wide range of bacteria. This study aimed to determine the fosfomycin susceptibility of E. coli causing UTI in a tertiary care hospital in Western Maharashtra, India.\\n\\nMaterial and methods: The study was conducted at a tertiary care center in Pune, a city of Western Maharashtra, India. Urine samples from UTI cases yielding significant (> 1x 105 cfu/ml) growth of E. coli were included in study. E. coli isolates were tested for susceptibility to fosfomycin and a panel of antimicrobial agents by Kirby Bauer disc diffusion method. All the isolates were tested for production of ESBL, AmpC and MBL.\\n\\nResult: A total of 88 E. coli were isolated of which, 47 (53.40%) and 41 (46.59%) were from male and female patients respectively. Of the total E. coli isolates, 58 (65.9%) were from in-patient cases. Multi-drug resistance was found in 69 (78.40%) isolates and remaining 19 (21.6%) were resistant to different antimicrobials tested. All (100%) the MDR and non-MDR isolates were sensitive to fosfomycin. Highest resistance was present against nalidixic acid (93.8%) while resistance was least against nitrofurantoin (15.91%), piperacillin/tazobactam (17.1%) and meropenem (18.18%). Of the total, 35 (50.72%) isolates were both AmpC and ESBL producers while 11 (15.94%) and 8 (11.59%) were only AmpC and ESBL producers respectively. MBL was positive in 15 (21.73%) of E. coli isolates. All those isolates tested sensitive to fosfomycin.\\n\\nConclusion: The study revealed that fosfomycin had excellent activity against MDR E. coli causing UTI in our area.\\n\\nIMC J Med Sci. 2023; 17(1): 008. DOI: https://doi.org/10.55010/imcjms.17.008\\n\\n*Correspondence: Dr. Sameena Khan, Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India. E-mail: sameenak27@gmail.com\",\"PeriodicalId\":55816,\"journal\":{\"name\":\"IMC Journal of Medical Science\",\"volume\":\"131 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IMC Journal of Medical Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55010/imcjms.17.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IMC Journal of Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55010/imcjms.17.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景与目的:尿路感染(UTI)是临床上最常见的细菌感染之一。由广谱β -内酰胺酶(ESBL) AmpC和产生金属β -内酰胺酶(MBL)的大肠杆菌(E. coli)引起的uti是难以治疗的。磷霉素是一种古老的抗生素,对多种细菌具有优良的杀菌活性。本研究旨在确定在印度马哈拉施特拉邦西部一家三级保健医院引起尿路感染的大肠杆菌对磷霉素的敏感性。材料和方法:本研究在印度马哈拉施特拉邦西部城市浦那的一家三级保健中心进行。研究纳入了大肠杆菌显著(> 1 × 105 cfu/ml)生长的尿路感染病例的尿液样本。采用Kirby Bauer圆盘扩散法检测大肠杆菌对磷霉素和一组抗菌药物的敏感性。所有分离株均进行了ESBL、AmpC和MBL的生产试验。结果:共分离到大肠杆菌88株,其中男、女患者分别分离到47株(53.40%)和41株(46.59%)。大肠杆菌分离株中,58株(65.9%)来自住院病例。69株(78.40%)发现多重耐药,其余19株(21.6%)对不同抗菌素耐药。所有(100%)耐多药和非耐多药菌株对磷霉素敏感。对萘啶酸的耐药率最高(93.8%),对呋喃妥英(15.91%)、哌拉西林/他唑巴坦(17.1%)和美罗培南(18.18%)的耐药率最低。同时产生AmpC和ESBL的菌株35株(50.72%),同时产生AmpC和ESBL的菌株11株(15.94%)和8株(11.59%)。15株(21.73%)大肠杆菌MBL阳性。所有分离株均对磷霉素敏感。结论:磷霉素对耐多药大肠杆菌引起的尿路感染具有良好的抑制作用。中华医学会医学杂志。2023;17(1): 008。DOI: https://doi.org/10.55010/imcjms.17.008*Correspondence: Sameena Khan博士,微生物系,Dr. Y. Patil医学院,医院和研究中心,Dr. Y. Patil Vidyapeeth,印度马哈拉施特拉邦,浦那,Pimpri。电子邮件:sameenak27@gmail.com
Fosfomycin susceptibility among Escherichia coli causing urinary tract infection in a tertiary care centre in Western Maharashtra
Background and objective: Urinary tract infection(UTI) is one of the most common bacterial infections encountered in clinical practice. UTIs caused by extended-spectrum beta-lactamase (ESBL) AmpC and metallo-beta-lactamase (MBL) producing Escherichia coli (E. coli) are difficult to treat. Fosfomycin is an old antibiotic that has excellent bactericidal activity against a wide range of bacteria. This study aimed to determine the fosfomycin susceptibility of E. coli causing UTI in a tertiary care hospital in Western Maharashtra, India.
Material and methods: The study was conducted at a tertiary care center in Pune, a city of Western Maharashtra, India. Urine samples from UTI cases yielding significant (> 1x 105 cfu/ml) growth of E. coli were included in study. E. coli isolates were tested for susceptibility to fosfomycin and a panel of antimicrobial agents by Kirby Bauer disc diffusion method. All the isolates were tested for production of ESBL, AmpC and MBL.
Result: A total of 88 E. coli were isolated of which, 47 (53.40%) and 41 (46.59%) were from male and female patients respectively. Of the total E. coli isolates, 58 (65.9%) were from in-patient cases. Multi-drug resistance was found in 69 (78.40%) isolates and remaining 19 (21.6%) were resistant to different antimicrobials tested. All (100%) the MDR and non-MDR isolates were sensitive to fosfomycin. Highest resistance was present against nalidixic acid (93.8%) while resistance was least against nitrofurantoin (15.91%), piperacillin/tazobactam (17.1%) and meropenem (18.18%). Of the total, 35 (50.72%) isolates were both AmpC and ESBL producers while 11 (15.94%) and 8 (11.59%) were only AmpC and ESBL producers respectively. MBL was positive in 15 (21.73%) of E. coli isolates. All those isolates tested sensitive to fosfomycin.
Conclusion: The study revealed that fosfomycin had excellent activity against MDR E. coli causing UTI in our area.
IMC J Med Sci. 2023; 17(1): 008. DOI: https://doi.org/10.55010/imcjms.17.008
*Correspondence: Dr. Sameena Khan, Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India. E-mail: sameenak27@gmail.com